Merck & Co., Inc. (ETR:6MK)
Germany · Delayed Price · Currency is EUR | Market Cap | 214.12B |
| Revenue (ttm) | 54.75B |
| Net Income (ttm) | 16.22B |
| Shares Out | n/a |
| EPS (ttm) | 6.44 |
| PE Ratio | 13.20 |
| Forward PE | 11.04 |
| Dividend | 2.86 (3.32%) |
| Ex-Dividend Date | Dec 15, 2025 |
| Volume | 672 |
| Average Volume | 3,073 |
| Open | 85.70 |
| Previous Close | 85.40 |
| Day's Range | 85.60 - 86.70 |
| 52-Week Range | 65.50 - 99.10 |
| Beta | 0.30 |
| RSI | 58.12 |
| Earnings Date | Feb 3, 2026 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial numbers in USD Financial StatementsNews
Notable analyst calls this week: Paypal, Rivian and Merck among top picks
Trump Secures Drug Price Cuts From 9 Major Pharma Firms Including Bristol Myers, Gilead, Merck In Medicaid Deal
President Donald Trump and nine major pharmaceutical companies announced agreements to lower the cost of medications for cash payers and the government’s Medicaid program on Friday, bringing U.S. cost...
Top Research Reports for NVIDIA, Netflix & Merck
New research highlights NVIDIA's AI-driven growth, Netflix's ad-tier momentum and Merck's pipeline progress, while microcaps also make the cut.
FDA Prioritizes Merck (MRK) Products for Enhanced Patient Access
FDA Prioritizes Merck (MRK) Products for Enhanced Patient Access
Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay
The companies, including Bristol-Myers Squibb, GSK and Merck, would avoid potential U.S. tariffs in return.
US FDA grants priority vouchers to Merck's cholesterol pill, cancer therapy
The U.S. Food and Drug Administration said on Friday it has granted national priority vouchers to Merck's cholesterol pill and its cancer therapy, making them the latest additions to the fast-track pr...
Merck (MRK) Strikes Deal to Make Prescription Drugs More Affordable
Merck (MRK) Strikes Deal to Make Prescription Drugs More Affordable
Why Health Care ETFs Aren't Panicking Over Big Pharma's Price Cuts
As big pharmaceutical companies are set to finalize a deal with the U.S. government to bring down prices for some prescription drugs, another old question is coming into focus for investors: how much ...
Trump strikes deal with US drugmakers to cut Medicaid medicine costs
Officials pledge ‘massive savings’ as companies agree to offer drugs at prices equal to those in other wealthy nations Donald Trump and nine major pharmaceutical companies on Friday announced deals th...
Better Buy in 2026: Pfizer or Merck?
This year has been one to forget for these pharmaceutical giants.
Dow Jones' Merck, Other Drugmakers Strike Drug-Pricing Bargains With Trump
Dow Jones stock Merck struck a Most Favored Nation agreement with the Trump administration on Friday, joining other pharma bellwethers.
Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans.
Nine of the largest pharma companies ink deals with Trump to lower drug prices
Several of the largest U.S. and European-based drugmakers inked deals with President Donald Trump to voluntarily sell their medications for less, as his administration pushes to link the nation's drug...
Evaxion Seeks New Partner For Gonorrhea Vaccine After Merck Opts Out
Merck & Co. Inc. (NYSE: MRK) will not exercise its option for Evaxion A/S (NASDAQ: EVAX) Gonorrhea vaccine candidate EVX-B2 . Gonorrhoea is a common, sexually transmitted infection caused by Neisser...
Trump to announce new drug-pricing deals later today
The White House is getting ready to announce more deals with drugmakers aimed at lowering drug prices.
Analysts Sound Alarm On Pyxis Oncology's Tiny Trial
Pyxis Oncology Inc. (NASDAQ: PYXS) on Thursday released preliminary data from its ongoing Phase 1 studies of micvotabart pelidotin (MICVO) for recurrent/metastatic head and neck squamous cell carcino...
Peter Lynch Detailed Fundamental Analysis - MRK
Below is Validea's guru fundamental report for MERCK & CO INC (MRK). Of the 22 guru strategies we follow, MRK rates highest using our P/E/Growth Investor model based on the published strategy of Peter...
Merck (MRK) Declines Option on Evaxion's Gonorrhea Vaccine
Merck (MRK) Declines Option on Evaxion's Gonorrhea Vaccine
AbbVie, Bristol Myers, Merck among latest to announce U.S. drug pricing deals: Reuters
AbbVie (ABBV), Bristol Myers Squibb (BMY), Gilead (GILD), and Merck (MRK) are set to annouce U.S. drug pricing deals. Read more here.
Merck's Deep Pipeline And Cash Flow Strength Support The Bull Case
Merck (MRK) Rises Higher Than Market: Key Facts
In the latest trading session, Merck (MRK) closed at $100.69, marking a +1.52% move from the previous day.
Merck (MRK) Upgraded to Outperform with Price Target Raised to $130
Merck (MRK) Upgraded to Outperform with Price Target Raised to $130
Merck Cholesterol, Cancer Drugs May Enter FDA Fast-Track Program: Report
The U.S. Food and Drug Administration (FDA) is preparing to fast-track reviews of two experimental Merck & Co. Inc . (NYSE: MRK) drugs with potential blockbuster sales . Merck's cholesterol treatment...
Merck Cholesterol, Cancer Drugs May Enter FDA Fast-Track Program: Report
The U.S. Food and Drug Administration (FDA) is preparing to fast-track reviews of two experimental Merck & Co. Inc. (NYSE: MRK) drugs with potential blockbuster sales.